10x Genomics, Inc. (TXG) stock
TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30106% above fair value
$56.30+1.31 (+2.38%)
Close on Nov 17, 2026Market cap $7.34BP/E –Yield –
10x Genomics cash
Cash and short-term investments held at the end of each period.
10x Genomics's cash was $575.68M at Sep 30, 2026. For fiscal 2025 it was $523.41M, up 33.0% from the year before. The highest annual figure on record is $688.64M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $523.41M | +33.0% |
| FY2024 | Dec 31, 2024 | $393.40M | +1.2% |
| FY2023 | Dec 31, 2023 | $388.70M | -11.2% |
| FY2022 | Dec 31, 2022 | $437.59M | -26.6% |
| FY2021 | Dec 31, 2021 | $596.07M | -13.4% |
| FY2020 | Dec 31, 2020 | $688.64M | +44.5% |
| FY2019 | Dec 31, 2019 | $476.49M | +579.8% |
| FY2018 | Dec 31, 2018 | $70.09M | +46.5% |
| FY2017 | Dec 31, 2017 | $47.86M | +14.6% |
| FY2016 | Dec 31, 2016 | $41.74M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $575.68M | +19.4% |
| Q2 FY2026 | Jun 30, 2026 | $552.03M | +23.4% |
| Q1 FY2026 | Mar 31, 2026 | $539.85M | +26.5% |
| Q4 FY2025 | Dec 31, 2025 | $523.41M | +33.0% |
| Q3 FY2025 | Sep 30, 2025 | $482.29M | +21.1% |
| Q2 FY2025 | Jun 30, 2025 | $447.26M | +17.7% |
| Q1 FY2025 | Mar 31, 2025 | $426.91M | +14.8% |
| Q4 FY2024 | Dec 31, 2024 | $393.40M | +1.2% |
| Q3 FY2024 | Sep 30, 2024 | $398.16M | +10.5% |
| Q2 FY2024 | Jun 30, 2024 | $380.09M | -4.1% |
| Q1 FY2024 | Mar 31, 2024 | $371.81M | -12.7% |
| Q4 FY2023 | Dec 31, 2023 | $388.70M | -11.2% |
| Q3 FY2023 | Sep 30, 2023 | $360.38M | -21.7% |
| Q2 FY2023 | Jun 30, 2023 | $396.36M | -21.9% |
| Q1 FY2023 | Mar 31, 2023 | $425.76M | -22.2% |
| Q4 FY2022 | Dec 31, 2022 | $437.59M | -26.6% |
| Q3 FY2022 | Sep 30, 2022 | $459.99M | -24.5% |
| Q2 FY2022 | Jun 30, 2022 | $507.34M | -21.8% |
| Q1 FY2022 | Mar 31, 2022 | $546.95M | -15.1% |
| Q4 FY2021 | Dec 31, 2021 | $596.07M | -13.4% |
| Q3 FY2021 | Sep 30, 2021 | $609.07M | -26.9% |
| Q2 FY2021 | Jun 30, 2021 | $648.71M | +60.7% |
| Q1 FY2021 | Mar 31, 2021 | $643.96M | +49.1% |
| Q4 FY2020 | Dec 31, 2020 | $688.64M | +44.5% |
| Q3 FY2020 | Sep 30, 2020 | $833.70M | +74.6% |
| Q2 FY2020 | Jun 30, 2020 | $403.69M | +561.3% |
| Q1 FY2020 | Mar 31, 2020 | $431.90M | +508.7% |
| Q4 FY2019 | Dec 31, 2019 | $476.49M | +579.8% |
| Q3 FY2019 | Sep 30, 2019 | $477.49M | +442.2% |
| Q2 FY2019 | Jun 30, 2019 | $61.04M | +27.6% |
| Q1 FY2019 | Mar 31, 2019 | $70.96M | +70.0% |
| Q4 FY2018 | Dec 31, 2018 | $70.09M | – |
| Q3 FY2018 | Sep 30, 2018 | $88.07M | – |
| Q4 FY2017 | Dec 31, 2017 | $47.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $41.74M | – |
See a number that looks wrong?